| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
34,330,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Co.'s therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection, or CHB, VTP-200 for the treatment of human papilloma virus infection, or HPV, VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer, or NSCLC. Co.'s prophylactic programs include VTP-400 for the prevention of herpes zoster, or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome, or MERS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
23,750 |
23,750 |
| Total Buy Value |
$0 |
$0 |
$61,012 |
$61,012 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
84,133 |
| Total Sell Value |
$0 |
$0 |
$0 |
$461,553 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
14 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scheeren Joseph |
Director |
– • – |
2022-04-01 |
4 |
B |
$5.09 |
$50,900 |
D/D |
10,000 |
13,000 |
2.39 |
- |
|
| Hammacher Alex |
Director |
– • – |
2022-03-31 |
4 |
B |
$5.14 |
$10,280 |
D/D |
2,000 |
3,000 |
2.39 |
- |
|
| Hammacher Alex |
Director |
– • – |
2021-12-31 |
4 |
B |
$10.86 |
$10,860 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
| Wright Robin |
Director |
– • – |
2021-12-22 |
4 |
B |
$9.97 |
$99,700 |
D/D |
10,000 |
34,506 |
2.39 |
- |
|
| Enright William |
Chief Executive Officer |
• • – |
2021-05-04 |
4/A |
A |
$0.00 |
$0 |
D/D |
514,923 |
1,258,377 |
|
- |
|
| Griffiths Graham |
Chief Business Officer |
• – – |
2021-05-04 |
4 |
B |
$17.00 |
$1,700 |
D/D |
100 |
100 |
2.66 |
- |
|
| Phillips Anne M. |
Director |
– • – |
2021-05-04 |
4 |
B |
$17.00 |
$51,000 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| Oxford Sciences Innovation Plc |
10% Owner |
– – • |
2021-05-04 |
4 |
B |
$17.00 |
$10,200,000 |
D/D |
600,000 |
8,797,770 |
2.45 |
- |
|
| Oxford Sciences Innovation Plc |
10% Owner |
– – • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,197,770 |
8,197,770 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2021-05-04 |
4 |
B |
$17.00 |
$28,900 |
D/D |
1,700 |
1,700 |
2.39 |
- |
|
| Ellis Christopher |
Chief Operating Officer |
• – – |
2021-05-04 |
4 |
B |
$17.00 |
$1,275 |
D/D |
75 |
75 |
2.66 |
- |
|
| Wright Robin |
Director |
– • – |
2021-05-04 |
4 |
B |
$17.00 |
$238,000 |
D/D |
14,000 |
24,506 |
2.39 |
- |
|
| Scheeren Joseph |
Director |
– • – |
2021-05-04 |
4 |
B |
$17.00 |
$51,000 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| M&g Investment Management Ltd |
10% Owner |
– – • |
2021-04-30 |
4 |
B |
$14.40 |
$1,800,000 |
I/I |
125,000 |
1,088,597 |
1.5 |
- |
|
| M&g Alternatives Investment Management Ltd |
10% Owner |
– – • |
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,108,752 |
|
- |
|
| Enright William |
Chief Executive Officer |
• • – |
2021-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
455,775 |
1,199,229 |
|
- |
|
| M&g Investment Management Ltd |
10% Owner |
– – • |
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
963,597 |
|
- |
|
| Morgon Pierre A. |
Director |
– • – |
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,506 |
|
- |
|
| Wright Robin |
Director |
– • – |
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,506 |
|
- |
|
| Enright William |
Chief Executive OfficerOfficer |
• • – |
2021-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
743,454 |
|
- |
|
45 Records found
|
|
Page 2 of 2 |
|
|
